Skip to main content
Premium Trial:

Request an Annual Quote

James Cornelius, Lewis Campbell, James Robinson III, John Cottingham, Louis Lange, Thomas West, Stephen Kurtz, James Posada, Kavita Reddy, Tina-Cheng Avery, Jens Peter (JP) Timm, Stephanie Seidman, Stephanie Jungersen, Else Beth Trautner, Leonard Lavin, U

Premium
Bristol-Myers Squibb CEO Adds Board Chairman Duties
 
James Cornelius, CEO of Bristol-Myers Squibb, has been elected chairman of the pharmaceutical giant’s board of directors. Cornelius will continue as CEO, the position he has filled since April 2007, following seven months as interim CEO. He joined the board in January 2005.
 
Prior to joining BMS, Cornelius served as chairman emeritus of the Guidant board of directors upon closing of its merger into Boston Scientific in April 2006. Previously he had been Guidant’s chairman and CEO during the merger process and was responsible for the company's initial public offering and subsequent split-off from Eli Lilly and Company in 1995.
 
Cornelius was a member of the board of directors of Eli Lilly, a member of its executive committee and CFO from 1983 to 1995. From 1980 to 1982, he served as president and CEO of IVAC Corporation, previously an Eli Lilly subsidiary.
 
Cornelius was born in Kalamazoo, Mich., and attended Michigan State University, where he graduated magna cum laude with a BA degree in accounting in 1965 and an MBA in 1967.
 
The BMS board also named as lead independent director Lewis Campbell, the chairman, president and CEO of Textron Inc. James Robinson III, co-founder and general partner of RRE Ventures, resigned as non-executive chairman of the board, a position he had held since June 2005. He will remain a director of the company until May 6, the date of the BMS board’s annual meting, when he will retire pursuant to its mandatory age retirement policy.
 

 
New Directors Elected to California Healthcare Institute Board
 
Three life sciences executives have been elected to the board of directors of the California Healthcare Institute, a La Jolla, Calif,., public policy research group representing more than 250 member academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms:
  • John Cottingham, senior vice president, general counsel and corporate secretary of Invitrogen. Cottingham previously served as general counsel and assistant secretary of Life Technologies, which merged with Invitrogen. He has also served as an international corporate attorney with the Washington, DC, office of Fulbright and Jaworski. He received his bachelor’s degree in political science from Furman University, his JD degree from the University of South Carolina, his master of law degree in securities regulation from Georgetown University, and his master of science in executive leadership from the University of San Diego.
  • Louis Lange, chairman and CEO of CV Therapeutics, a biopharmaceutical company. One of the first academicians in molecular cardiology, Lange previously served on the faculty of the Washington University School of Medicine, including a position as chief of cardiology at the Jewish Hospital in St. Louis, and as a full professor of medicine. Lange holds an MD from Harvard Medical School and a PhD in biochemistry from Harvard University.
  • Thomas West, president of North America LifeScan, a division of Johnson & Johnson that manufactures glucose monitoring systems. West has held consumer products, over-the-counter and prescription pharmaceuticals positions with LifeScan, as well as leadership positions covering general management, marketing, international franchise management and business development in 16 years with J&J. West holds an MBA from the Wharton School of the University of Pennsylvania, and a bachelor’s degree in political economy from Princeton University.

 
Znomics Hires Director of Operations, Advisor for Business Development
 
Znomics, a Portland, Ore., developer of a drug discovery platform based on mutation of the zebrafish, has named two professionals to new executive positions:
 
Stephen Kurtz has been promoted to director of operations, effective March 1. Kurtz will be responsible for expanding the company’s drug discovery program by evaluating new technologies at universities and companies for possible in-licensing opportunities. He will also oversee some laboratory operations as well as team up with university and corporate scientists that collaborate with Znomics.
 
James Posada has been named a business advisor to assist with business development. Posada's will seek to develop the company’s collaborative programs with potential pharmaceutical and biotechnology partners. He will also oversee technology in-licensing and out-licensing activities for Znomics.
 
Kurtz was previously chief scientific officer at Northwest NeuroLogic, associate director and scientist at Neurocrine Biosciences, and senior scientist at Bristol-Myers Squibb. Earlier, he was a postdoctoral fellow at Columbia University.
 
Kurtz earned a bachelor's degree in biology from Brown University, and a doctorate degree in molecular genetics and cell biology from the University of Chicago.
 
Posada was previously senior vice president for business and market development at Glycofi, a 60-person start-up company spun out of Dartmouth University. While at Glycofi, Posada was instrumental in negotiating strategic collaborations with both Merck and Eli Lilly, which led to Merck's acquisition of Glycofi. Earlier, Posada served as senior director for business development at Protein Design Labs, manager of a therapeutic protein division at Eli Lilly, and assistant professor of biophysics and molecular biology at the University of Vermont Medical School.
 
Posada earned a BSci degree in biology from Eastern Connecticut State University, a PhD degree in molecular and cellular biology from the University of Vermont School of Medicine, and an MBA degree from University of Vermont School of Business.
 

 
Genzyme Genetics Manhattan Executive Joins CombiMatrix as Laboratory Director
 
Kavita Reddy has joined CombiMatrix Molecular Diagnostics of Mukilteo, Wash., as laboratory director.
 
Reddy joins CMDX from Genzyme Genetics Manhattan, where she was senior director. Previously, she was associate director and scientific director with Quest Diagnostics at the Nichols Institute, and has been a consultant with the City of Hope Cancer Center and US Labs, now Laboratory Corporation of America.
 
Reddy earned a PhD from the Bangalore University, India, and was then awarded a Wellcome Trust Postdoctoral fellowship to the UK’s MRC Radiobiology Unit.
 

 
Pierre Fabre Marketing VP Named Commercialization VP for Medical Device Maker
 
Tina Cheng-Avery has been appointed to the newly created position of vice president of commercialization with Electro-Optical Sciences, a medical device company in the New York City suburb of Irvington, NY, focused on developing MelaFind, a non-invasive, point-of-care instrument intended to assist in the early diagnosis of melanoma.
 
Cheng-Avery previously served as vice president of marketing at Pierre Fabre Dermo-Cosmetique USA/Genesis Pharmaceutical, where she managed the Avène and Glytone dermo-cosmetic skincare product lines distributed through dermatologist and plastic surgeon offices.
 
Previously, Cheng-Avery was global marketing director for skin care at Elizabeth Arden, where she managed a $300 million skin care portfolio. She also led a collaboration between Elizabeth Arden and Allergen Pharmaceuticals, and was responsible for launching Prevage anti-aging treatment.
 
Cheng-Avery earlier served as vice president of marketing for Wella Personal Care of North America, group product director at Johnson & Johnson’s Neutrogena Corporation, and associate brand manager for Aveeno at S.C. Johnson & Family, Inc.
 
Cheng-Avery holds an MBA degree from Northwestern University.
 

 
Alphatec Names Spinal Orthopedics Executive as Research and Development VP
 
Jens Peter (JP) Timm has been named vice president of research and development of Alphatec Holdings, a Carlsbad, Calif., manufacturer of products for the surgical treatment of spine disorders.
 
Timm previously held a similar position at Applied Spine Technologies since 2004. From 1999 to 2004, Timm served in various engineering and R&D capacities at Interpore Cross International, most recently as director of development for anterior fusion and disc systems. Timm served as a development engineer with Biomet from 1997 to 1999
 
Timm earned a BSci degree in biomedical engineering from Rensselaer Polytechnic Institute in Troy, NY.
 

 
Biotech Patent Attorney Named to Head Law Firm’s Life Sciences Group
 
Stephanie Seidman has joined the law firm Bell Boyd & Lloyd, where she will head the Life Sciences Group formed following the law firm’s expansion into San Diego (see Around the Regions, this issue). Seidman will provide strategic counseling to clients regarding development and commercialization of patent portfolios affecting the biopharma industry.
 
Seidman is a biotechnology patent attorney who holds a PhD in molecular biology and biochemistry and MSci and BSci degrees in chemistry and physics. She has been nominated for the University of California, San Diego, Athena Pinnacle Award that honors women who have made a significant impact on the San Diego life sciences community. In 2006, the San Diego Business Journal selected her as the recipient of their Women Who Mean Business Award.
 

 
Economic Development Council Promotes Jungersen to Business Development VP

Stephanie Jungersen has been promoted by the San Diego North Economic Development Council to vice president of business development. Jungersen will be responsible for strategic planning, marketing, business recruitment and retention along with representing the organization on various boards and advisory groups.
 
Jungersen started with the council as an international intern in the spring of 2005. Since then, she has held positions as a marketing assistant and lead project manager.
 

 
Molecular Diagnostics Product Maker Taps Dako Executive as Sales and Marketing VP
 
Else Beth Trautner has been named vice president of sales and marketing for AdvanDx, a Woburn, Mass., manufacturer of molecular diagnostics products.
 
Trautner previously served as executive vice president of global sales at Dako, a global cancer diagnostics company, where she restructured business operations in the Asia-Pacific region, leading to record sales. Trautner also orchestrated the reorganization of 22 sales subsidiaries into five geographic regions, resulting in 15-percent sales growth and a 9-percent increase in profitability.
 

 
Alberto-Culver Founder Joins Board of San Diego Regenerative Medicine Company
 
Leonard Lavin, founder and chairman emeritus of the Alberto-Culver Company, has joined the board of directors of Histogen, a year-old San Diego regenerative medicine company.
 
Lavin and his wife Bernice bought Alberto-Culver in 1955 for $400,000, and grew it into a multi-billion-dollar revenue company. In addition to his career with Alberto-Culver, a Fortune 1000 consumer products company, Lavin also built the toiletry product maker Halgar and formed the Excello Sales Agency, where he gained exclusive advertising and sales rights for Stopette, which emerged as a leading spray deodorant as a pioneer television advertiser during the 1950s.
 

 
Nevada Biotechnology Group Honors Sen. Harry Reid at Awards Luncheon
 
US Sen. Harry Reid (D-Nev.) has been selected as the inaugural recipient of a biotechnology award named for him by the Nevada Biotechnology and Bioscience Consortium at its Nevada Biotechnology Awards luncheon, held Feb. 18 at the Wynn Hotel in Las Vegas.
 
Reid is being honored for his support of higher education in Nevada, and is credited with securing more than $100 million for the state’s universities. "Senator Reid has arguably been the State's leading supporter of higher education here,” consortium president John Laub said in a statement.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.